Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | BAD | Q92934 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NQO1 | P15559 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630475 | 0.96 | BCL2L1 (0.52) | BCL2L1BADGRIA1GRIA2GRIA3 | |
| SCHEMBL16239399 | 0.79 | BCL2L1 (0.52) | BCL2L1BADPARP1GRIA1GRIA2 | |
| SCHEMBL1535927 | 0.77 | BCL2L1 (0.50) | BCL2L1BAD | |
| SCHEMBL1284960 | 0.75 | BCL2L1 (0.58) | BCL2L1BADPARP1GRIA1GRIA2 | |
| SCHEMBL22989664 | 0.74 | PARP1 (0.39) | BCL2L1BADPARP1NOS3NOS1 | |
| SCHEMBL13091628 | 0.74 | NOS3 (0.39) | BCL2L1BADPARP1ALDH1A1NOS3 | |
| SCHEMBL22990006 | 0.74 | PNMT (0.43) | BCL2L1BADPARP1 | |
| SCHEMBL11317199 | 0.74 | BCL2L1 (0.47) | BCL2L1BADPARP1GRIA1GRIA2 | |
| SCHEMBL30047413 | 0.74 | BCL2L1 (0.47) | BCL2L1BADPARP1POLBESR1 | |
| SCHEMBL2046938 | 0.74 | BCL2L1 (0.42) | BCL2L1BADPARP1GRIA1GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12168653-B2 | Sulfonamide derivates as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-12-17 | — | — | US | disclosed |
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-07-09 | — | — | US | disclosed |
| US-11884645-B2 | Sulfonyl acetamides as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-01-30 | — | — | US | disclosed |
| US-11834433-B2 | Compounds | INFLAZOME LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-11834433-B2 | Compounds | INFLAZOME LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-11834433-B2 | Compounds | INFLAZOME LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-11530200-B2 | Compounds | INFLAZOME LIMITED (IE) | 2022-12-20 | — | — | US | disclosed |
| US-20210047302-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-02-18 | — | — | US | disclosed |
| US-20210040065-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-02-11 | — | — | US | disclosed |
| US-20210002274-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-01-07 | — | — | US | disclosed |
| US-20200407340-A1 | SULFONAMIDE DERIVATES AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2020-12-31 | — | — | US | disclosed |
| US-20200399243-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-12-24 | — | — | US | disclosed |
| US-6964965-B2 | Substituted pyrazine derivatives | PHARMACIA & UPJOHN (US) | 2005-11-15 | — | — | US | disclosed |
| EP-1499599-A1 | SUBSTITUTED PYRAZINE DERIVATIVES | Pharmacia & Upjohn Company LLC (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040053941-A1 | Substituted pyrazine derivatives | PHARMACIA & UPJOHN COMPANY | 2004-03-18 | — | — | US | disclosed |
| WO-2003091225-A1 | SUBSTITUTED PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053941-A1 | Substituted pyrazine derivatives | CRHR1, CRHR2, CRH | BCL2L1 4127/4885BAD 2606/4885PARP1 2688/4885 |
| US-20210047302-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, CBR3 | BCL2L1 1809/4885BAD 649/4885PARP1 516/4885 |
| US-20210040065-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | BCL2L1 1317/4885BAD 263/4885PARP1 258/4885 |
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | BCL2L1 2485/4885BAD 1563/4885PARP1 1414/4885 |
| US-20200407340-A1 | SULFONAMIDE DERIVATES AS NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | BCL2L1 2876/4885BAD 1766/4885PARP1 880/4885 |
| US-20200399243-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | BCL2L1 1973/4885BAD 800/4885PARP1 477/4885 |
| US-11884645-B2 | Sulfonyl acetamides as NLRP3 inhibitors | NLRP3, NOD1, ABCC5 | BCL2L1 2062/4885BAD 1716/4885PARP1 1619/4885 |
| US-11834433-B2 | Compounds | NLRP3, NOD1, PYCARD | BCL2L1 1499/4885BAD 334/4885PARP1 258/4885 |
| US-20210002274-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | BCL2L1 2481/4885BAD 988/4885PARP1 659/4885 |
| US-12168653-B2 | Sulfonamide derivates as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | BCL2L1 2876/4885BAD 1766/4885PARP1 880/4885 |
| US-11530200-B2 | Compounds | NLRP3, NOD1, NLRP1 | BCL2L1 1757/4885BAD 670/4885PARP1 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.